Changes in Pituitary Iron and Volume With Deferasirox

Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Iron Overload Iron Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

2 year–25 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Currently on chronic transfusion therapy.
Duration of chronic transfusion >1 year.
Age 2 to 25 years
On deferasirox monotherapy for the duration of the study.
Informed consent from legal guardian and/or patient.
On deferasirox for a minimum of 3 months at start of study.

Exclusion criteria

Sickle cell disease or sickle-beta zero genotype.
Combination of deferasirox and another iron chelator.

Sponsors and collaborators

Lead sponsor

Children's Hospital Los Angeles

Other

Collaborators

Novartis Pharmaceuticals

Registry information

Official study title

Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload

Important dates

Study start: 2008
Primary completion: 2011
Study completion: 2011
First posted: Jun 20, 2011
Registry last updated: Oct 31, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed